Mosby's 2014 Nursing Drug Reference (263 page)

BOOK: Mosby's 2014 Nursing Drug Reference
10.39Mb size Format: txt, pdf, ePub
ads
methylphenidate (Rx)

(meth-ill-fen′i-date)

Biphentin
, Concerta, Daytrana, Metadate CD, Metadate ER, Methylin, Quillivant XR, Ritalin, Ritalin LA, Ritalin SR

Func. class.:
Cerebral stimulant

Chem. class.:
Piperidine derivative

 

Controlled Substance Schedule II

Do not confuse:
methylphenidate
/methadone

ACTION:

Increases release of norepinephrine, dopamine in cerebral cortex to reticular activating system; exact action not known

USES:

Attention deficit disorder (ADD), attention-deficit/hyperactivity disorder (ADHD); narcolepsy (except Concerta, Metadate CD, Ritalin LA)

CONTRAINDICATIONS:

Children <6 yr, hypersensitivity, anxiety, history of Gilles de la Tourette’s syndrome; glaucoma, anorexia nervosa, tartrazine dye hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, hypertension, depression, seizures

 

Black Box Warning:

Substance abuse

DOSAGE AND ROUTES
Calculator
Attention-deficit/hyperactivity disorder (ADHD) initial treatment, not currently on methylphenidate
Regular release: Ritalin, methylin, methylin oral sol, methylin chew tabs

• Adult:
PO
20-30 mg/day, range 10-60 mg/day in 2-3 divided doses, 30-45 min before meals

• Child ≥6 yr:
PO
5 mg bid initially, increase 5-10 mg/day weekly, usual dose 0.3-2 mg/kg/day, max 60 mg/day

Extended release: Ritalin SR, metadate ER, methylin ER

• Adult/adolescent/child ≥6 yr:
PO
max 20-30 mg tid

Extended-release once-daily tabs: Concerta

• Adult:
PO
18-36 mg/day initially then adjust by 18 mg/wk, max 72 mg/day

• Adolescent:
PO
18 mg/day initially then adjust by 18 mg/wk, max 72 mg/day

• Child ≥6 yr:
PO
18 mg/day initially then adjust by 18 mg/wk, max 54 mg/day

Extended-release once-daily capsules: Ritalin LA

• Adult/adolescent/child ≥6 yr:
PO
20 mg daily in
AM
initially, adjust by 10 mg/wk, max 60 mg/day

Extended-release once-daily capsules: Metadate CD

• Adult/adolescent/child ≥6 yr:
PO
20 mg/day in
AM
, adjust by 20 mg/wk, max 60 mg/day

Transdermal: Daytrana

• Adolescent/child ≥6 yr:
TD
wk 1: 10 mg/day (9-mg patch); wk 2: 15 mg/day (9-mg patch); wk 3: 20 mg/day (9-mg patch); wk 4: 30 mg/day (9-mg patch)

Conversion to once-daily treatment from other forms for ADHD
Extended-release once-daily capsules: Metadate CD

• Adult/adolescent/child ≥6 yr:
PO
give no more than total daily dose of other forms, may adjust by 20 mg/wk, max 60 mg/day

Extended-release once-daily capsules: Ritalin LA

• Adult/adolescent/child ≥6 yr:
PO
give no more than total daily dose of other forms, may adjust by 10 mg/wk, max 60 mg/day

Extended-release once-daily tablets: Concerta

• Adult/adolescent/child ≥6 yr (currently on 10-15 mg/day):
PO
18 mg every
AM
initially, adjust by 18 mg/wk, max 72 mg/day (adult); max 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child) mg/day

• Adult/adolescent/child ≥6 yr (currently receiving 20-30 mg/day):
PO
36 mg every
AM
, adjust by 18 mg/wk, max 72 mg/day (adult); 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child)

• Adult/adolescent/child ≥6 yr (currently receiving 30-45 mg/day):
PO
54 mg every
AM
, adjust by 18 mg/wk, max 72 mg/day (adult); 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child)

• Adult/adolescent/child ≥6 yr (currently receiving 40-60 mg/day):
PO
72 mg every
AM
, 72 mg/day

Extended-release once-daily suspension: Quillivant XR

• Adolescents/child ≥6 yr:
PO
give in
AM
, increase in 10-20 mg increments q week

Narcolepsy
Immediate release: Ritalin, methylin oral sol, methylin chew tabs

• Adult:
PO
20-30 mg/day, range 10-60 mg/day in 2-3 divided doses

• Child ≥6 yr:
PO
5 mg bid, may increase by 5-10 mg/wk, max 60 mg/day

Extended-release tabs: Ritalin SR, metadate ER

• Adult/adolescent/child ≥6 yr:
PO
max 20 mg tid

Poststroke depression; major depression (unlabeled)

• Adult and geriatric:
PO
(immediate rel tabs) 2.5 mg bid, may increase by 2.5-5 mg q2-3days

Available forms:
Tabs 5, 10, 20 mg; ext rel tabs 10, 20, mg; ext rel tabs (Concerta) 18, 27, 36, 54 mg; ext rel caps 10, 20, 30, 40 mg; oral sol 5 mg, 10 mg/ml; chew tabs (Methylin) 2.5, 5, 10 mg; transdermal patch 12.5 cm
2
(10 mg), 18.75 cm
2
(15 mg), 25 cm
2
(20 mg), 37.5 cm
2
(30 mg); ext rel oral susp 300 mg/60 ml, 600 mg/120 ml, 750 mg/150 ml, 900 mg/180 ml

Administer:
PO route

• 
Do not crush, chew ext rel product; caps may be opened, beads sprinkled over spoonful of applesauce; give without regard to meals

• 
Gum, hard candy, frequent sips of water for dry mouth

• 
Give immediate rel dose 30-45 min before meals

• 
Chew tab
with adequate water to prevent choking; contains phenylalanine

• 
Avoid metadate CD on day of surgery

Extended release oral suspension (quillivant XR)

• 
Shake bottle well, use calibrated dosing dispenser provided, give in
AM
without regard to meals, reconstitute as per manufacturer

Transdermal route

• 
Place on clean, dry area of hip; avoid waist; remove 9 hr after application; fold after removal, flush down toilet

• 
If patch falls off, apply new patch to different site; total wear time should be 9 hr

SIDE EFFECTS

CNS:
Hyperactivity, insomnia, restlessness, talkativeness
, dizziness, drowsiness, toxic psychosis, headache, akathisia, dyskinesia, masking or worsening of Tourette’s syndrome,
seizures,
hallucinations,
malignant neuroleptic syndrome,
aggression;
cerebral vasculitis, hemorrhage, stroke (rare)

CV:
Palpitations, tachycardia
, B/P changes, angina,
dysrhythmias

ENDO:
Growth retardation

GI:
Nausea, anorexia, dry mouth, weight loss, abdominal pain

HEMA:
Leukopenia, anemia, thrombocytopenic purpura

INTEG:
Exfoliative dermatitis,
urticaria, rash, erythema multiforme,
hypersensitivity reactions

MISC:
Fever, arthralgia, scalp hair loss

PHARMACOKINETICS

PO:
Onset 1/2-1 hr, duration 4-6 hr, metabolized by liver, excreted by kidneys, half-life 3-4 hr

INTERACTIONS

• 
Hypertensive crisis: MAOIs or within 14 days of MAOIs, vasopressors

Increase:
effects of tricyclics, SSRIs, anticonvulsants, SNRIs, CNS stimulants

Decrease:
effect of antihypertensives

Drug/Herb

Increase:
CNS stimulation—cola nut, guarana, horsetail, yerba maté, yohimbe

Drug/Food

Increase:
stimulation—caffeine

NURSING CONSIDERATIONS
Assess:

• 
ADHD:
attention span, decreased hyperactivity

 

Black Box Warning:

Substance abuse: There is a high potential for abuse, use caution in those with history of substance abuse

• 
VS, B/P; may reverse antihypertensives; check patients with cardiac disease more often for increased B/P

• 
CBC with differential, platelets, LFTs, urinalysis; in diabetes: blood glucose, urine glucose; insulin changes may have to be made because eating will decrease

• 
Height, growth rate q3mo in children; growth rate may be decreased, but normal growth will resume when product is discontinued

• 
Mental status: mood, sensorium, affect, stimulation, insomnia, aggressiveness

 
Withdrawal symptoms:
headache, nausea, vomiting, muscle pain, weakness, usually not associated with drug holidays

• 
Appetite, sleep, speech patterns

• 
Narcolepsy:
identify frequency, length of narcoleptic episodes

Evaluate:

• 
Therapeutic response: decreased hyperactivity (ADHD); increased ability to stay awake (narcolepsy)

Teach patient/family:

• 
To decrease caffeine consumption (coffee, tea, cola, chocolate), may increase irritability, stimulation; not to use guarana, yerba maté, cola nut

• 
To avoid OTC preparations unless approved by prescriber

• 
To taper off product over several weeks because depression, increased sleeping, lethargy will occur

• 
To avoid driving, hazardous activities if dizziness, blurred vision occur

• 
To avoid alcohol

• 
To avoid hazardous activities until stabilized on medication

• 
To get needed rest; patients will feel more tired at end of day

• 
That shell of Concerta tab may appear in stools

• 
To take regular tab at least 6 hr prior to sleep, 10 hr for ext rel, use dosing syringe to measure liquid; do not use household teaspoon

• 
Transdermal:
after tray is opened, use within 2 mo; do not store patches without protective patch, notify prescriber if skin irritation or rash occurs

TREATMENT OF OVERDOSE:

Administer fluids; hemodialysis or peritoneal dialysis; antihypertensive for increased B/P; administer short-acting barbiturate before lavage

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

BOOK: Mosby's 2014 Nursing Drug Reference
10.39Mb size Format: txt, pdf, ePub
ads

Other books

The Temptation (Kindred) by Valdes, Alisa
Love Medicine by Louise Erdrich
The Pack-Retribution by LM Preston
A Little Friendly Advice by Siobhan Vivian
Ready To Go by Mann, Stephanie
Bottom Feeder by Deborah LeBlanc
Home to Roost by Tessa Hainsworth